Compare Bristol-Myers Squibb Co (BMY) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.63 (market cap $132.45B), while YieldMax MSTR Option Income Strategy ETF trades at $12.54. The key difference: Bristol-Myers Squibb Co pays a 3.89% dividend while YieldMax MSTR Option Income Strategy ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| BMY | MSTY | |
|---|---|---|
Market Cap | $132.45B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $65.89 | $95.95 |
52-Week Low | $42.60 | $11.55 |
Enterprise Value | $166.44B | — |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MSTY (YieldMax MSTR Option Income Strategy ETF) trades at $12.82, up 2.31% today, but remains in a significant downtrend with a 67% decline year-to-date. The ETF faces structural challenges as high distribution yields mask substantial NAV erosion, with technical indicators showing neutral momentum amid bearish moving averages. Recent news highlights concerns about the fund returning investor capital as distributions while experiencing deep losses.
The outlook remains challenged by the ETF's structural limitations that cap upside potential while exposing investors to full downside risk. Investment opportunity exists only for sophisticated investors seeking high current income despite principal erosion, while risks include continued NAV decline, tax inefficiency, and dependence on MicroStrategy's volatile performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
